Staff Profile

Roles and Responsibilities

Head of University Department of Haematology with responsibility for administration of University staff and non-medical research staff. Examiner at all levels of undergraduate teaching. Supervisor of B.Med Sci projects. Clinical Director of Haematological Services for Newcastle Hospitals NHS Trust, (excluding NHS Laboratory Services).

Qualifications

FRCP, FRCPath

Previous Positions

Previous member of the University Research Committee and Faculty Research Committee.

Memberships

REGIONAL: Lead clinician for Regional Haematology audit, linked closely to the Regional Research Programme. Co-organiser of the total regional data collection on haematological malignancy. Member of the Northern Region Consultant Haematology Group (previous Chairman). Chairman of the Regional Leukaemia/Lymphoma Research organisation and member of the Regional Research and Development Advisory Committee. Previous member of the Northern & Yorkshire Regional Committee for Implementation of the Calman Cancer Proposals. NATIONAL: Fellow of the Royal College of Physicians, Fellow of the Royal College of Pathologists. Joint Regional Advisor to the British Society of Haematology and College of Pathologists. Member of the UK Cancer Research Study Group for Marrow Transplant in the UK. Executive member of the UK Cancer Co-ordinating Committee for Lymphoma. Member of the national Leukaemia Research Fund Scientific Group. INTERNATIONAL: Member of the European Bone Marrow Transplant Group. Member of the International Society of Haematology. Member of the New York Academy of Sciences. Visiting assessor of INSERM Research Units in France. Regularly invited guest speaker to international congresses. EDITORIAL: Board Member of Leukaemia and Bone Marrow Transplantation Journals.

Research Interests

Extensive expertise in clinico-laboratory research in leukaemia in adults. (Immunology, biochemical, molecular biological and clinical aspects) Clinical trials in leukaemia (adult) and malignant lymphoma. Population study methodology in haematology and cancer. Organisation of regional and supra-regional clinical and laboratory study groups in haematological oncology. (PACE - population adusted clinical epidemiology group).

Other Expertise

Experienced clinical teacher and post-graduate trainer for Specialist Registrars. Organisation and management of academic and clinical departments. Consultant for introduction of PACE programmes in diverse areas of medicine.

Future Research

During the existence of the clinico-laboratory group, major experience and results have allowed the team to be regarded as one of the UK leaders in management and investigation in acute lymphoblastic leukaemia in adults, Hodgkin's disease and aspects of non-Hodgkin's lymphoma. Much of the laboratory programme relates to these diseases. In addition, the group is regarded as one of the leaders in investigation of graft versus host disease biology in vitro. The overall clinical programme has developed to provide a novel population-based approach to clinical research work, designated as population-adjusted clinical epidemiology (PACE). The next four years will see evolution and progression in all the above mentioned areas with an emphasis taken on applied laboratory activity related to the clinical research areas indicated. It is anticipated that Newcastle will become the major organisational centre for haematological clinical research on a supra-regional basis, including Scotland and the rest of the North of England.

Funding

1980 - 2000 Several million pounds in regional and national research grants. Leukaemia Research Fund Centre 1988 to 1996. Current staff of 35, 80% externally funded. EU grant 2001 (Dr Anne Dickinson lead investigator) 2.2 MILLION ECU. £1.5 million funding for new academic unit 2001 - 2002.

• Proctor SJ, Taylor PRA. A practical guide to continuous population-based data collection (PACE): a process facilitating uniformity of care and research into practice. QJM: An International Journal of Medicine 2000, 93(2), 67-73.
• Middleton PG, Norden J, Levett DL, Levasseur M, Miller S, Irving JAE, Wood A, Reid MM, Taylor PRA, Proctor SJ. Population-based study of the pattern of molecular markers of minimal residual disease in childhood and adult acute lymphoblastic leukemia: An assessment of the practical difficulty of representative sampling for trial purposes. Medical and Pediatric Oncology 2000, 34(2), 106-110.
• Stiller, C. A., Benjamin, S., Cartwright, R. A., Clough, J. V., Gorst, D. W., Kroll, M. E., Ross, J. R. Y., Wheatley, K., Whittaker, J. A., Taylor, P. R. A., Proctor, S. J. Patterns of care and survival for adolescents and young adults with acute leukaemia - a population-based study. British Journal of Cancer 1999, 79(3-4), 658-665.
• Dickinson AM, Hromadníková I, Sviland L, Jackson GH, Taylor PRA, Vavrinec J, Sedlacek P, Cermáková M, Starý J, Vitek A, Sajdová J, Proctor SJ. Use of a skin explant model for predicting GVHD in HLA-matched bone marrow transplants - effect of GVHD prophylaxis. Bone Marrow Transplantation 1999, 24(8), 857-863.
• Hasenclever D, Diehl V, Armitage JO, Assouline D, Bjorkholm M, Brusamolino E, Canellos GP, Carde P, Crowther D, Cunningham D, Eghbali H, Ferm C, Fisher RI, Glick JH, Glimelius B, Gobbi PG, Holte H, Horning SJ, Lister TA, Longo DL, Mandelli F, Polliack A, Proctor SJ, Specht L, Sweetenham JW, VaughanHudson G. A prognostic score for advanced Hodgkin's disease. New England Journal of Medicine 1998, 339(21), 1506-1514.
• Legras, S., Gunthert, U., Stauder, R., Curt, F., Oliferenko, S., Kluin-Nelemans, H. C., Marie, J. P., Proctor, S. J., Jasmin, C., Smadja-Joffe, F. A strong expression of CD44-6v correlates with shorter survival of patients with acute myeloid leukemia. Blood 1998, 91(9), 3401-3413.
• Jackson, G. H., Taylor, P. R. A., Iqbal, A., Galloway, M. J., Turner, G., Haynes, A., Hamilton, P. J., Russell, N., Proctor, S. J. The use of an all oral chemotherapy (idarubicin and etoposide) in the treatment of acute myeloid leukaemia in the elderly: a report of toxicity and efficacy. Leukemia 1997, 11(8), 1193-1196.
• Hurst EC, Maniou-Fowler T, Sieniawski M, Angus B, Proctor S, Lennard A, Culpin R. Impact of p53 positive p21 negative phenotype on outcome in CHOP-R treated DLBCL patients. In: 54th Annual Scientific Meeting of the British Society for Haematology. 2014, Birmingham, UK: Wiley-Blackwell.
• Culpin RE, Sieniawski M, Angus B, Menon GK, Proctor SJ, Milne P, McCabe K, Mainou-Fowler T. Prognostic significance of immunohistochemistry-based markers and algorithms in immunochemotherapy-treated diffuse large B-cell lymphoma patients. Histopathology 2013, 63(6), 788-801.
• Proctor SJ, Wilkinson J, Jones G, Watson GC, Lucraft HH, Mainou-Fowler T, Culligan D, Galloway MJ, Wood KM, McNally RJ, James PW, Goodlad JR. Evaluation of treatment outcome in 175 patients with Hodgkin lymphoma aged 60 years or over: the SHIELD study. Blood 2012, 119(25), 6005-6015.
• Proctor SJ, Wilkinson J, Culligan D, Galloway M, Lucraft HH, Jones G, Mcnally R, Wood KM, Mainou-Fowler T, Watson G, Goodlad JR. Comparative clinical responses of three chemotherapy schedules (VEPEMB, ABVD, CLVPP) in 175 Hodgkin Lymphoma patients over 60ys evaluated as part of the Shield (Hodgkin elderly) Study. In: Annals of Oncology: 11th International Conference on Malignant Lymphoma. 2011, Lugano, Switzerland: Oxford University Press.
• Culpin RE, Proctor SJ, Angus B, Crosier S, Anderson JJ, Mainou-Fowler T. A 9 series microRNA signature differentiates between germinal centre and activated B-cell-like diffuse large B-cell lymphoma cell lines. International Journal of Oncology 2010, 37(2), 367-376.
• Culpin RE, Anderson JJ, Angus B, Proctor SJ, Crosier S, Mainou-Fowler T. A 9 series microRNA signature differentiates between germinal centre and activated B-cell-like diffuse large B-cell lymphoma cell lines. In: EJC Supplements: 21st Meeting of the European Association for Cancer Research. 2010, Oslo, Norway: Pergamon.
• Culpin RE, Pearce K, Bailey JR, Sunter NJ, Pointon JC, Proctor SJ, Allsup DJ, Allan JM, Fowler TM. Mature MicroRNAs Mir 18, 19a, 19b, 17 5p and 92 of the Mir 17 92 Cluster Predict for Treatment Free Survival In Patients with Chronic Lymphocytic Leukaemia. In: Blood: 52nd Annual Meeting of the American Society of Hematology (ASH). 2010, Orlando, Florida, USA: American Society of Hematology.
• Culpin RE, Pearce K, Bailey JR, Sunter NJ, Pointon JC, Proctor SJ, Allsup DJ, Allan JM, Mainou-Fowler T. Mature MicroRNAs Mir-18,-19a,-19b,-17-5p and-92 of the Mir-17-92 Cluster Predict for Treatment Free Survival In Patients with Chronic Lymphocytic Leukaemia. In: Blood: 52nd Annual Meeting of the American Society of Hematology. 2010, Orlando, Florida, USA: American Society of Hematology.
• Maung ZT, Reid MM, Proctor SJ, Taylor PRA, Matheson E, Hall AG. Corticosteroid resistance: An important biological difference between childhood and adult acute lymphoblastic leukemia. In: DRUG RESISTANCE IN LEUKEMIA AND LYMPHOMA II. 1997, POSTSTRASSE 22, 7000 CHUR, SWITZERLAND: HARWOOD ACADEMIC PUBL GMBH.
• Proctor SJ, Taylor PRA. The use of oral idarubicin, chlorambucil and dexamethasone in low-grade non-Hodgkin's lymphoma. In: ORAL CYTOTOXIC TREATMENT IN HAEMATOLOGICAL MALIGNANCIES. 1996, CHAPEL PLACE, ROYAL TUNBRIDGE WELLS, KENT, ENGLAND TN1 1BP: WELLS MEDICAL LTD.
• PROCTOR SJ, TAYLOR P, MACKIE MJ, DONNAN P, BOYS R, LENNARD A, PRESCOTT RJ, ALLAN NC, DAS SN, DAWSON AA, HEPPLESTONE A, LEONARD RCF, LUCRAFT HH, MACLAREN KS, PARKER AC, RITCHIE GL, SARKAR TK, SCOTT JS, WHITE J, ANGUS B, CURTIS M, MCGILLAVRAY JB. A NUMERICAL PROGNOSTIC INDEX FOR CLINICAL USE IN IDENTIFICATION OF POOR-RISK PATIENTS WITH HODGKINS-DISEASE AT DIAGNOSIS. LEUKEMIA & LYMPHOMA 1992, 7, 17-20.
• PROCTOR SJ, JACKSON GH, LENNARD AL, MARKS J. LYMPHOMATOID PAPULOSIS - RESPONSE TO TREATMENT WITH RECOMBINANT INTERFERON ALFA-2B. JOURNAL OF CLINICAL ONCOLOGY 1992, 10(1), 170-170.
• PROCTOR SJ. ALPHA-INTERFERON THERAPY IN THE TREATMENT OF IDIOPATHIC THROMBOCYTOPENIC PURPURA. EUROPEAN JOURNAL OF CANCER 1991, 27, S63-S68.
• SVILAND L, PEARSON ADJ, GREEN MA, BAKER BDL, EASTHAM EJ, REID MM, HAMILTON PJ, PROCTOR SJ, MALCOLM AJ. IMMUNOPATHOLOGY OF EARLY GRAFT-VERSUS-HOST DISEASE - A PROSPECTIVE-STUDY OF SKIN, RECTUM, AND PERIPHERAL-BLOOD IN ALLOGENEIC AND AUTOLOGOUS BONE-MARROW TRANSPLANT RECIPIENTS. TRANSPLANTATION 1991, 52(6), 1029-1036.